CLLS is Cellectis S.A. (Healthcare) — a non-dividend-paying stock. Trading at $3.24. Market cap: $326M.
Stock snapshot
| Price | $3.24 |
| Market cap | $326M |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
About CLLS
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Related non-dividend companies
Other non-dividend stocks investors research alongside CLLS. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is CLLS's current stock price?
CLLS (Cellectis S.A.) is currently trading at $3.24.
Does CLLS pay a dividend?
CLLS (Cellectis S.A.) does not currently pay a regular dividend.
Track CLLS in DiviDrip
Add CLLS to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search CLLS and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-06. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.